These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26664109)

  • 1. COPD exacerbation frequency and its association with health care resource utilization and costs.
    Dhamane AD; Moretz C; Zhou Y; Burslem K; Saverno K; Jain G; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2609-18. PubMed ID: 26664109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
    Moll K; Sun SX; Ellis JJ; Howe A; Amin A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
    Schwab P; Dhamane AD; Hopson SD; Moretz C; Annavarapu S; Burslem K; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2017; 12():735-744. PubMed ID: 28260880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
    Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS; DePietro M; McPheeters J; Fox KM
    Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population.
    Coutinho AD; Lokhandwala T; Boggs RL; Dalal AA; Landsman-Blumberg PB; Priest J; Stempel DA
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1223-31. PubMed ID: 27354781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.
    Gerhardsson de Verdier M; Andersson M; Kern DM; Zhou S; Tunceli O
    Value Health; 2015 Sep; 18(6):759-66. PubMed ID: 26409602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea.
    Kim C; Yoo KH; Rhee CK; Yoon HK; Kim YS; Lee SW; Oh YM; Lee SD; Lee JH; Kim KJ; Kim JH; Park YB
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):737-43. PubMed ID: 24903947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COPD symptom burden: impact on health care resource utilization, and work and activity impairment.
    Ding B; Small M; Bergström G; Holmgren U
    Int J Chron Obstruct Pulmon Dis; 2017; 12():677-689. PubMed ID: 28260874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
    Wan Y; Sun SX; Corman S; Huang X; Gao X; Shorr AF
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2127-36. PubMed ID: 26504378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC; Lau H; La HO; Choi IS; Geba GP
    Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.
    Chen YJ; Makin C; Bollu VK; Navaie M; Celli BR
    J Med Econ; 2016; 19(1):11-20. PubMed ID: 26357881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and Costs.
    Jain R; Cai Q; Sun SX; Tan H
    Manag Care; 2015 Aug; 24(8):40-8. PubMed ID: 26399141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory-related medical expenditure and inpatient utilisation among COPD patients receiving long-acting bronchodilator therapy.
    Cao Z; Zou KH; Baker CL; Su J; Paulose-Ram R; Durden E; Shi N; Shah H
    J Med Econ; 2011; 14(2):147-58. PubMed ID: 21288057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new method for examining the cost savings of reducing COPD exacerbations.
    Mapel DW; Schum M; Lydick E; Marton JP
    Pharmacoeconomics; 2010; 28(9):733-49. PubMed ID: 20799755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD.
    Yu AP; Guérin A; de Leon DP; Ramakrishnan K; Wu EQ; Mocarski M; Blum SI; Setyawan J
    Respir Med; 2011 Dec; 105(12):1861-71. PubMed ID: 21807487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.